for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion



A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas


Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care therapies compared to those with EBV-negative disease. Nanatinostat is a selective class I HDAC inhibitor which induces EBV lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational, single-arm, basket study employs a Simon's 2-stage design to allow termination of enrollment into cohorts where treatment appears futile, and will include the following cohorts of patients with EBV+ relapsed/refractory lymphomas: This is an open-label, multicenter, multinational single-arm, Phase 2 basket design study, utilizing Simon's 2-stage design. The study will include 7 cohorts of patients with the following EBV+ relapsed/refractory lymphomas: 1. EBV+ diffuse large B-cell lymphoma (DLBCL, NOS) 2. Extranodal NK/T-cell lymphoma (ENKTL) 3. Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL 4. Hodgkin lymphoma (HL) 5. Post-transplant lymphoproliferative disorder (PTLD) 6. HIV-associated lymphomas (Plasmablastic, Burkitt, Hodgkin, DLBCL) 7. EBV+ lymphoproliferative disorders other than the above


Epstein-Barr Virus Associated Lymphoproliferative Disorder EBV-Related PTLD EBV Related Non-Hodgkin's Lymphoma Extranodal NK/T-cell Lymphoma EBV-Positive DLBCL, Nos EBV Associated Lymphoma EBV-Related Hodgkin Lymphoma EBV Related PTCL, Nos EBV positive post-transplant lymphoproliferative disorder (PTLD) EBV lymphoma HIV-associated lymphoma Lymphoproliferative Disorders Epstein-Barr Virus (EBV) EBV positive T cell lymphoma Lymphoma Lymphoma, T-Cell Lymphoma, Extranodal NK-T-Cell Valganciclovir Nanatinostat in combination with valganciclovir


You can join if…

Open to people ages 18 years and up

  • EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies
  • EBV+ DLBCL, NOS: Must have received at least one course of an anti-CD20 immunotherapy, and at least one course of anthracycline-based chemotherapy
  • PTLD: Must have received immunotherapy with an anti-CD20 agent.
  • Hodgkin lymphoma: Must have received at least one course of anthracycline-based chemotherapy. Patients with classical Hodgkin lymphoma should have failed or be ineligible for an anti-PD-1 agent and CD30-directed therapy.
  • For extranodal NK/T-cell lymphoma patients only: Relapsed/refractory disease following 1 or more prior systemic therapies. Patients must have failed an asparaginase-containing regimen.
  • No available therapies in the opinion of the Investigator
  • Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T therapy
  • Measurable disease per Lugano 2007
  • ECOG performance status 0, 1, 2
  • Adequate bone marrow function

You CAN'T join if...

  • Presence or history of CNS involvement by lymphoma
  • Systemic anticancer therapy or CAR-T within 21 days
  • Antibody (anticancer) agents within 28 days
  • Less than 60 days from prior autologous hematopoietic stem cell or solid organ transplant
  • Less than 90 days from prior allogeneic transplant.
  • Daily corticosteroids (≥20 mg of prednisone or equivalent) within week prior to Cycle 1 Day 1
  • Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir.
  • Active infection requiring systemic therapy (excluding viral upper respiratory tract infections).


  • University of California Irvine not yet accepting patients
    Orange California 92868 United States
  • The Oncology Institute of Hope and Innovation accepting new patients
    Torrance California 90503 United States


accepting new patients
Start Date
Completion Date
Viracta Therapeutics, Inc.
Phase 2
Study Type
Last Updated